{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:45:39Z","timestamp":1791326739838,"version":"4.3.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.pharmthera.2016.11.009","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T19:46:57Z","timestamp":1480621617000},"page":"205-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["New horizons for cystic fibrosis treatment"],"prefix":"10.1016","volume":"170","author":[{"given":"Isabelle","family":"Fajac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"De Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2016.11.009_bb0005","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/18744672112059990025","article-title":"ENaC inhibitors and airway re-hydration in cystic fibrosis: State of the art","volume":"6","author":"Althaus","year":"2013","journal-title":"Current Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0020","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0025","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1002\/ppul.23543","article-title":"Genetic medicines for CF: Hype versus reality","volume":"51","author":"Alton","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0030","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1093\/hmg\/dds345","article-title":"Cystic fibrosis in an era of genomically guided therapy","volume":"21","author":"Barrett","year":"2012","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-015-0223-6","article-title":"Targeted therapies to improve CFTR function in cystic fibrosis","volume":"7","author":"Brodlie","year":"2015","journal-title":"Genome Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1183\/09031936.00196314","article-title":"Future trends in cystic fibrosis demography in 34 European countries","volume":"46","author":"Burgel","year":"2015","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nm.2715","article-title":"Cystic fibrosis: A mucosal immunodeficiency syndrome","volume":"18","author":"Cohen","year":"2012","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0060","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.201009-1478CI","article-title":"Managing cystic fibrosis: Strategies that increase life expectancy and improve quality of life","volume":"183","author":"Cohen-Cymberknoh","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.11.009_bb0065","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2014.03.009","article-title":"European cystic fibrosis society standards of care: Framework for the cystic fibrosis Centre","volume":"13","author":"Conway","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0070","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","author":"De Boeck","year":"2016","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0085","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0090","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"De Boeck","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0095","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0100","doi-asserted-by":"crossref","first-page":"36639","DOI":"10.1074\/jbc.M112.393637","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner","volume":"287","author":"Eckford","year":"2012","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2008.03.007","article-title":"The prevalence of cystic fibrosis in the European Union","volume":"7","author":"Farrell","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0110","doi-asserted-by":"crossref","first-page":"a009480","DOI":"10.1101\/cshperspect.a009480","article-title":"Assessing the disease-liability of mutations in CFTR","volume":"2","author":"Ferec","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cgh.2012.11.006","article-title":"Gastrointestinal complications of cystic fibrosis","volume":"11","author":"Gelfond","year":"2013","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0120","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1089\/hum.2015.027","article-title":"Cystic fibrosis Gene therapy in the UK and elsewhere","volume":"26","author":"Griesenbach","year":"2015","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0125","doi-asserted-by":"crossref","first-page":"a009498","DOI":"10.1101\/cshperspect.a009498","article-title":"The CFTR ion channel: Gating, regulation, and anion permeation","volume":"3","author":"Hwang","year":"2013","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0130","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0135","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0140","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI0215217","article-title":"Mucus clearance as a primary innate defense mechanism for mammalian airways","volume":"109","author":"Knowles","year":"2002","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005599.pub4","article-title":"Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease","author":"Lee","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0150","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17476348.2016.1177460","article-title":"Pseudomonas aeruginosa infection in cystic fibrosis: Pathophysiological mechanisms and therapeutic approaches","volume":"10","author":"Lund-Palau","year":"2016","journal-title":"Expert Review of Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0155","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-0636","article-title":"Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: Survival analysis of the Cystic Fibrosis Foundation patient registry","volume":"161","author":"MacKenzie","year":"2014","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0160","first-page":"1","article-title":"Pathophysiology of cystic fibrosis lung disease","volume":"64","author":"Mall","year":"2014","journal-title":"European Respiratory Monograph"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0165","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jcf.2015.06.002","article-title":"Targeting ion channels in cystic fibrosis","volume":"14","author":"Mall","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0170","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/thoraxjnl-2015-208123","article-title":"Advancing clinical development pathways for new CFTR modulators in cystic fibrosis","volume":"71","author":"Mayer-Hamblett","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0175","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: A phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0180","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fphar.2012.00160","article-title":"Functional rescue of F508del-CFTR using small molecule correctors","volume":"3","author":"Molinski","year":"2012","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0185","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2012.11.034","article-title":"Pitfalls of drug development: Lessons learned from trials of denufosol in cystic fibrosis","volume":"162","author":"Moss","year":"2013","journal-title":"The Journal of Pediatrics"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0190","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: A double-blind, randomised controlled trial","volume":"3","author":"Moss","year":"2015","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0195","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores DeltaF508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11130","article-title":"Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung","volume":"487","author":"Pezzulo","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0205","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(08)61162-9","article-title":"Cystic fibrosis: Impaired bicarbonate secretion and mucoviscidosis","volume":"372","author":"Quinton","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0210","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0215","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1091\/mbc.E13-05-0240","article-title":"VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1","volume":"24","author":"Ren","year":"2013","journal-title":"Molecular Biology of the Cell"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0220","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0225","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0230","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0235","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","article-title":"Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis","volume":"182","author":"Sermet-Gaudelus","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0240","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0245","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0250","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0255","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0260","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2016.03.028","article-title":"N-of-1 trials to enhance patient outcomes: Identifying effective therapies and reducing harms, one patient at a time","author":"Vohra","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0270","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0275","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0280","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0285","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0290","doi-asserted-by":"crossref","first-page":"L263","DOI":"10.1152\/ajplung.00269.2014","article-title":"Augmentation of CFTR maturation by S-nitrosoglutathione reductase","volume":"310","author":"Zaman","year":"2016","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0295","doi-asserted-by":"crossref","first-page":"8150","DOI":"10.1073\/pnas.0401933101","article-title":"Reversal of cystic fibrosis phenotype in a cultured Delta508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion","volume":"101","author":"Zamecnik","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2016.11.009_bb0300","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.ge.29.120195.004021","article-title":"Cystic fibrosis: Genotypic and phenotypic variations","volume":"29","author":"Zielenski","year":"1995","journal-title":"Annual Review of Genetics"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816302352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816302352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T07:52:34Z","timestamp":1536220354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725816302352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":60,"alternative-id":["S0163725816302352"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.11.009","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New horizons for cystic fibrosis treatment","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}